Immunotherapy improves five-year survival rate of people with advanced lung cancer
In a study led by UCLA investigators, treatment with the immunotherapy drug pembrolizumab helped more than 15 percent of people with advanced non-small cell lung cancer live for at least five years—and 25 percent of patients ...
Jun 3, 2019
0
199